随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
1.Yoast SEOThose users who are serious about SEO, Yoast SEO will do the work for them to reach their goals. All they need to do is select a keyword, and the plugin will then optimize your page according to the specified keyword，推荐阅读im钱包官方下载获取更多信息
，详情可参考爱思助手下载最新版本
These debt-funded projects create “indirect but potentially material” exposure to fiscal risk, the analysts wrote. Beyond infrastructure, governments will have to plan for labor disruptions and related social support. The IMF estimates 40% of global jobs—and 60% in advanced economies—are exposed to AI, particularly high-skill roles, potentially eroding payroll taxes while spiking demand for reskilling and safety nets.
https://feedx.site。关于这个话题，heLLoword翻译官方下载提供了深入分析